Castle Biosciences Q2 FY26 net loss widens to $2.1 million; revenue rises 20.1% to $103.5 million

Reuters2026/07/30 20:14

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Castle Biosciences posted Q2 revenue of USD 103.5 million, up 20.07% from a year earlier.
Net results swung to a loss of USD 2.1 million; loss per share was USD 0.07.
Adjusted EBITDA (non-GAAP) rose to USD 12.4 million; gross margin slipped 2.4 percentage points to 75%.
Core test reports climbed 32% year over year, with TissueCypher volumes rising to 14,988.
Raised 2026 revenue outlook to USD 365-375 million; expects positive adjusted EBITDA in Q3, Q4, and full-year 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607301605PR_NEWS_USPR_____DA14269) on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Castle Biosciences Q2 FY26 net loss widens to $2.1 million; revenue rises 20.1% to $103.5 million

You may also like

Crypto prices